This article presents a very high potential clinical impact and is recommended reading for all. Contrary to this article, other papers, using inferential and proscribed methods for relative rates of adverse events among different iron formulations, have come up with specious conclusions. Ferumoxytol was the victim of such ill-considered work. This well-conducted, properly powered, prospective, randomised trial shows conclusively that, in the absence of head-to-head trials or well-powered retrospective analyses, conclusions concerning the relative safety of different IV iron preparations cannot and should not be made.
– Michael Auerbach